BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 11182041)

  • 1. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
    Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel, carboplatin, and hexamethyl-melamine (taxchex) as first-line therapy for ovarian cancer.
    Hartenbach EM; Harris LS; Bailey HH; Grosen EA; Larrison E; Chen D; Twiggs LB; Schink JC
    Cancer J Sci Am; 1999; 5(6):348-55. PubMed ID: 10606476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
    Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
    Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
    Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
    Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C
    Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer.
    Watanabe Y; Nakai H; Ueda H; Hoshiai H
    Gynecol Oncol; 2005 Feb; 96(2):323-9. PubMed ID: 15661216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
    Gronlund B; Høgdall C; Hansen HH; Engelholm SA
    Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
    Meerpohl HG; du Bois A; Luck HJ; Kühnle H; Möbus V; Kreienberg R; Bauknecht T; Köchli O; Bochtler H; Diergarten K
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J
    Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
    Gordon AN; Hancock KC; Matthews CM; Messing M; Stringer CA; Doherty MG; Teneriello M
    Gynecol Oncol; 2002 Apr; 85(1):129-35. PubMed ID: 11925132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined chemotherapy with weekly paclitaxel and carboplatin for recurrent and refractory epithelial ovarian cancer--phase I study].
    Misawa A; Yasuda M
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1445-52. PubMed ID: 17033235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.
    Sehouli J; Stengel D; Elling D; Ortmann O; Blohmer J; Riess H; Lichtenegger W;
    Gynecol Oncol; 2002 May; 85(2):321-6. PubMed ID: 11972395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer.
    Bolis G
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):32-4. PubMed ID: 8553081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.